Anthrax MedKit Initiative Could Learn From OTC Studies – NDAC
This article was originally published in The Tan Sheet
Executive Summary
FDA’s Nonprescription Drugs Advisory Committee recommends the HHS sponsors of an antibiotic MedKit take lessons from OTC drug development. But many advisory panel members at an April 2 meeting did not see clear benefits of allowing home stockpiling of doxycycline to treat anthrax.
You may also be interested in...
OTC Anthrax MedKit Development Relies On Incremental Approach
HHS’ Biomedical Advanced Research and Development Authority will ask FDA and its advisors about the feasibility of an OTC antibiotic MedKit for anthrax treatment at an advisory committee meeting.
In Brief
Abbott Nutrition eyes U.S. launches
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.